Peptide Half-Life Extension: How Researchers Make Short-Lived Peptides Last Longer

Why native peptides clear in minutes and how researchers extend half-life: D-amino acids, cyclization, Aib substitution, fatty-acid albumin binding and PEGylation.

Share

Most natural peptide hormones disappear from circulation within minutes. That short lifetime is useful for the body, which needs fast on-off signals, but it is a major obstacle for researchers who want to study a peptide's effects over hours or days. A large part of modern peptide chemistry is about solving this problem. Many of the compounds discussed on this site, including CJC-1295, tirzepatide and retatrutide, are themselves products of half-life engineering. This article explains why native peptides clear so quickly and walks through the main strategies described in the published literature, with real examples from the papers that introduced them. It is written for researchers and is not a guide to any use in people.

Why native peptides clear so fast

A 2006 review in Amino Acids by Werle and Bernkop-Schnürch identifies two main reasons for short plasma half-lives: fast renal clearance and enzymatic degradation during circulation. A 2015 review in The AAPS Journal by Li Di at Pfizer adds that natural peptides typically have rapid clearance, low permeability and sometimes low solubility.

Enzymatic degradation. Blood and tissues are full of proteases. A clear example is dipeptidyl peptidase IV (DPP-IV). In 1993, Mentlein, Gallwitz and Schmidt reported in the European Journal of Biochemistry that purified DPP-IV removes the first two residues from peptides that start with Tyr-Ala or His-Ala, including GLP-1(7-36)amide, GIP and growth hormone-releasing factor (1-29)amide. When they incubated GIP or GLP-1 with human serum in vitro, the same truncated fragments appeared, and specific DPP-IV inhibitors completely blocked their formation. Because an intact N-terminus is required for activity in this peptide family, that single cut inactivates them.

Renal clearance. Small molecules pass easily through the kidney's filter. Most peptides are well below the size at which filtration slows down, so even an enzyme-resistant peptide can be removed quickly unless something increases its effective size.

Every strategy below targets one or both of these problems.

Strategy 1: Replace vulnerable residues

The most direct approach is to change the amino acids that enzymes recognize.

D-amino acids and truncation. Somatostatin is a 14-residue hormone with a very short half-life. In 1982, a Sandoz team led by Bauer reported in Life Sciences an eight-residue analogue, H-(D)Phe-Cys-Phe-(D)Trp-Lys-Thr-Cys-Thr(ol), code-named SMS 201-995 and later known as octreotide. The abstract describes it as highly resistant to degradation by pure enzymes and tissue homogenates and much longer acting than somatostatin in rats and rhesus monkeys. The Werle review cites this as a model case: shortening the sequence and swapping in D-amino acids took half-life from a few minutes to about 1.5 hours.

Non-natural residues at cleavage sites. Replacing the residue next to a protease cut site with one the enzyme cannot handle is a common fix for DPP-IV. Semaglutide, described below, carries the non-natural amino acid Aib (alpha-aminoisobutyric acid) at position 8 of the GLP-1 sequence for this reason.

Terminal capping. Acetylating the N-terminus or amidating the C-terminus removes free ends that exopeptidases attack. The Werle review lists N- and C-terminal modification among the standard tools.

Strategy 2: Cyclization

Ring-shaped peptides have no free ends for exopeptidases and are often more rigid, which can hide cleavage sites from endopeptidases. Octreotide is again an example: its two cysteines form a disulfide bridge that holds the molecule in a constrained ring. Cyclization through disulfides, lactam bridges or head-to-tail bonds is widely discussed in reviews of peptide stability, including the Di review.

Strategy 3: Albumin binding through fatty-acid chains

Serum albumin is abundant and stays in circulation for a long time. A peptide that binds albumin reversibly is protected from filtration and partly shielded from enzymes while bound. This idea drives much of the incretin peptide field.

Liraglutide's predecessors. In 2000, Knudsen and colleagues at Novo Nordisk reported in the Journal of Medicinal Chemistry a series of GLP-1 derivatives carrying fatty acids designed to bind serum albumin. All compounds with fatty acids of 12 carbons or longer were very protracted compared with GLP-1, and GLP-1 tolerated fatty acids of up to 16 carbons almost anywhere in the C-terminal part without large losses of potency. They also found that longer fatty acids cost more potency, and that adding two fatty-acid chains led to a considerable loss.

Semaglutide. In 2015, Lau and colleagues described the design of semaglutide in the same journal. The goal was to raise albumin affinity and secure full stability against metabolic degradation. Semaglutide has two substitutions compared with human GLP-1 (Aib8 and Arg34) and is derivatized at lysine 26 with a fatty-acid moiety and linker. Its GLP-1 receptor affinity was three-fold lower than liraglutide's, but albumin affinity was higher. In mini-pigs, the reported plasma half-life after intravenous administration was 46.1 hours. The paper is a clear illustration of a trade-off: a little receptor potency was given up for a large gain in duration.

Tirzepatide. A 2018 paper by Coskun and colleagues in Molecular Metabolism describes LY3298176, now known as tirzepatide, as a fatty-acid-modified peptide with dual GIP and GLP-1 receptor agonist activity, designed for a long-acting profile. Our retatrutide research overview covers a related multi-receptor incretin peptide.

Strategy 4: Covalent albumin bioconjugation

Instead of reversible binding, some designs attach a peptide permanently to albumin. In 2005, Jetté and colleagues at ConjuChem in Montreal reported in Endocrinology three maleimido derivatives of human GH-releasing factor (1-29). The reactive maleimide group links to the free thiol on cysteine 34 of serum albumin. All three albumin conjugates showed improved stability against DPP-IV in vitro and remained bioactive in cultured rat pituitary cells.

The best compound, CJC-1295, is a tetrasubstituted form of hGRF(1-29) with an added maleimidopropionamide-modified lysine at the C-terminus. In rats it was found in plasma beyond 72 hours, and western blotting showed CJC-1295 immunoreactivity on the albumin band from 15 minutes onward. This is the "DAC" (drug affinity complex) design. Material labelled CJC-1295 without DAC lacks this reactive group, so the Jetté findings cannot be transferred to it.

Strategy 5: PEGylation

Attaching polyethylene glycol (PEG) chains increases a peptide's size and shields it from enzymes. A 2003 review in Nature Reviews Drug Discovery by Harris and Chess explains that PEGylation increases molecular mass and protects against proteolysis, which improves pharmacokinetics. The Werle review cites a PEG conjugate of interferon alpha-2b with a 330-fold longer plasma half-life than the native protein. PEGylation is more common for larger proteins than for short research peptides, but it shows how adding size alone can slow kidney clearance.

What this means when reading research

  • Analogues are not interchangeable with their parent peptides. A substitution or fatty-acid chain can change receptor affinity, as semaglutide's three-fold lower affinity shows.
  • Half-life is model-specific. Figures like 46.1 hours in mini-pigs or beyond 72 hours in rats belong to that species and design.
  • Identity testing matters more for modified peptides. A missing fatty-acid chain or maleimide group changes the molecule entirely. Mass spectrometry on the certificate of analysis should match the full modified structure, not just the peptide backbone.

References

  • Werle M, Bernkop-Schnürch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006;30(4):351-367. PMID: 16622600. doi:10.1007/s00726-005-0289-3.
  • Di L. Strategic approaches to optimizing peptide ADME properties. The AAPS Journal. 2015;17(1):134-143. PMID: 25366889. doi:10.1208/s12248-014-9687-3.
  • Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. European Journal of Biochemistry. 1993;214(3):829-835. PMID: 8100523. doi:10.1111/j.1432-1033.1993.tb17986.x.
  • Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sciences. 1982;31(11):1133-1140. PMID: 6128648. doi:10.1016/0024-3205(82)90087-x.
  • Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. Journal of Medicinal Chemistry. 2000;43(9):1664-1669. PMID: 10794683. doi:10.1021/jm9909645.
  • Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015;58(18):7370-7380. PMID: 26308095. doi:10.1021/acs.jmedchem.5b00726.
  • Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism. 2018;18:3-14. PMID: 30473097. doi:10.1016/j.molmet.2018.09.009.
  • Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. PMID: 15817669. doi:10.1210/en.2004-1286.
  • Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nature Reviews Drug Discovery. 2003;2(3):214-221. PMID: 12612647. doi:10.1038/nrd1033.

Research use only. All products sold by Morpheus Research are intended strictly for laboratory research and are not for human or veterinary consumption. Nothing in this article is medical advice, and no statement here is intended to diagnose, treat, cure or prevent any condition. Study findings are reported as published and should not be read as evidence of effects in people.